Home » Stocks » VRAY

ViewRay, Inc. (VRAY)

Stock Price: $5.17 USD -0.02 (-0.39%)
Updated May 11, 2021 9:56 AM EDT - Market open
Market Cap 839.43M
Revenue (ttm) 58.29M
Net Income (ttm) -107.12M
Shares Out 160.14M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $5.17
Previous Close $5.19
Change ($) -0.02
Change (%) -0.39%
Day's Open 5.00
Day's Range 4.94 - 5.17
Day's Volume 177,881
52-Week Range 1.72 - 7.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ViewRay (VRAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...

1 day ago - Zacks Investment Research

The market liked the company's first-quarter update.

3 days ago - The Motley Fool

ViewRay (VRAY) delivered earnings and revenue surprises of -6.25% and 28.20%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

CLEVELAND, May 6, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Received s...

4 days ago - PRNewsWire

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

CLEVELAND, April 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2021 financial results. ViewRay will hold a conference call to...

3 weeks ago - PRNewsWire

CLEVELAND, March 15, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) ("the Company") today announced that Shahriar Matin, Chief Operating Officer, will leave the Company effective March 31, 2021. Mati...

1 month ago - PRNewsWire

CLEVELAND, March 5, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in the 21st Annual Oppenheimer Healthcare Conferenc...

2 months ago - PRNewsWire

ViewRay (VRAY) delivered earnings and revenue surprises of -5.88% and 2.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CLEVELAND, March 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and year ended December 31, 2020. Full Year 2020 Highlights...

2 months ago - PRNewsWire

ViewRay (NASDAQ:VRAY) announces its next round of earnings this Thursday, March 04. Here is Benzinga's look at ViewRay's Q4 earnings report.

2 months ago - Benzinga

CLEVELAND, Feb. 19, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2020 financial results. ViewRay will hold a conf...

2 months ago - PRNewsWire

CLEVELAND, Feb. 11, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Penn State Health has purchased a second MRIdian Linac joining other pioneering institutions from around the gl...

3 months ago - PRNewsWire

A big investor sells out of the company.

3 months ago - The Motley Fool

STOCKHOLM, Jan. 22, 2021 /PRNewswire/ -- Elekta AB (EKTA-B.ST) announced today that it has sold its 7.3 percent of the outstanding common stock (11,501,597 shares) in ViewRay, Inc. (Nasdaq:VRAY). Elekta...

3 months ago - PRNewsWire

CLEVELAND, Jan. 15, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) (the "Company") today announced that members of management will be participating in a fireside chat at the B. Riley Oncology Investo...

3 months ago - PRNewsWire

The company announced the pricing of a public offering of common stock.

4 months ago - The Motley Fool

CLEVELAND, Jan. 7, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, toda...

4 months ago - PRNewsWire

CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, toda...

4 months ago - PRNewsWire

CLEVELAND, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, toda...

4 months ago - PRNewsWire

CLEVELAND, Ohio, Jan. 4, 2021 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2020. The preliminary result...

4 months ago - PRNewsWire

CLEVELAND, Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake, President and CEO, is scheduled...

4 months ago - PRNewsWire

CLEVELAND, Dec. 22, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Seoul National University Hospital (SNUH), a leading healthcare facility in South Korea, h...

4 months ago - PRNewsWire

CLEVELAND, Dec. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Catharina Hospital in Eindhoven, Netherlands, also known as Catharina Ziekenhuis, has purchased a MRIdian® Lina...

4 months ago - PRNewsWire

CLEVELAND, Nov. 12, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Amsterdam University Medical Centers (Amsterdam UMC) has treated one thousand patients usi...

5 months ago - PRNewsWire

CLEVELAND, Nov. 10, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Universitair Ziekenhuis Brussels has purchased a MRIdian® Linac MRI-Guided Therapy System, a cutting-edge radia...

6 months ago - PRNewsWire

ViewRay, Inc. (VRAY) CEO Scott Drake on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

ViewRay (VRAY) delivered earnings and revenue surprises of -11.76% and 13.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

CLEVELAND, Oct. 21, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian® Linac MRI-guided radiation therapy system will be featured at the 2020 Annual Meeting of...

6 months ago - PRNewsWire

CLEVELAND, Oct. 14, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the Louis Stokes Cleveland VA Medical Center in Cleveland, Ohio has purchased the MRIdian® Linac MRI-Guided The...

6 months ago - PRNewsWire

ViewRay (VRAY) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

CLEVELAND, Sept. 24, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Chungnam National University Sejong Hospital in Sejong, South Korea has begun patient treatments with the MRId...

7 months ago - PRNewsWire

CLEVELAND, Sept. 4, 2020 /PRNewswire/ -- ViewRay, Inc.

8 months ago - PRNewsWire

CLEVELAND, Sept. 1, 2020 /PRNewswire/ -- ViewRay, Inc.

8 months ago - PRNewsWire

CLEVELAND, Aug. 13, 2020 /PRNewswire/ -- ViewRay, Inc.

8 months ago - PRNewsWire

CLEVELAND, Aug. 5, 2020 /PRNewswire/ -- ViewRay, Inc.

9 months ago - PRNewsWire

ViewRay's (VRAY) CEO Scott Drake on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

ViewRay (VRAY) delivered earnings and revenue surprises of -12.50% and 144.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

CLEVELAND, July 30, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2020.

9 months ago - PRNewsWire

ViewRay (VRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

9 months ago - Zacks Investment Research

CLEVELAND, July 13, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2020 financial results. ViewRay will hold a conference call to...

9 months ago - PRNewsWire

Despite market's roller-coaster ride, a handful of momentum stocks with a favorable Zacks Rank have provided double-digit returns so far in June.

Other stocks mentioned: CLW, CMC, DOMO, MNTA
10 months ago - Zacks Investment Research

Top Ranked Momentum Stocks to Buy for June 23rd

Other stocks mentioned: HEAR, SNBR, ZUO
10 months ago - Zacks Investment Research

CLEVELAND, June 3, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today grants of stock options and restricted stock units to Zach Stassen, Chief Financial Officer for the company. These aw...

11 months ago - PRNewsWire

CLEVELAND, May 27, 2020 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that Providence Portland Medical Center in Portland, Oregon has begun patient treatments with the MRIdian® MR-Guided ...

11 months ago - PRNewsWire

ViewRay's (VRAY) CEO Scott Drake on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

ViewRay (VRAY) delivered earnings and revenue surprises of 0.00% and 14.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

ViewRay (VRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

About VRAY

ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government ... [Read more...]

Industry
Medical Devices
Founded
2004
Stock Exchange
NASDAQ
Ticker Symbol
VRAY
Full Company Profile

Financial Performance

In 2020, ViewRay's revenue was $57.02 million, a decrease of -35.05% compared to the previous year's $87.78 million. Losses were -$107.91 million, -10.23% less than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ViewRay stock is "Buy." The 12-month stock price forecast is 6.41, which is an increase of 23.98% from the latest price.

Price Target
$6.41
(23.98% upside)
Analyst Consensus: Buy